金属类化疗药物的抗肿瘤作用和机制研究

化疗药物的抗肿瘤耐药作用和潜在机制研究

荣誉奖励：

1、2022年江苏省首批党建工作样板支部培育建设项目负责人

2、2019年-2020年东南大学优秀班主任标兵

3、2019年全国高等学校药学类专业微课教学大赛（药学教指委） 二等奖

4、2018年东南大学“至善青年学者”支持计划

5、2018年东南大学中泰国立奖教金三等奖

6、2018年东南大学青年教师微课竞赛二等奖

7、2017年东南大学青年教师授课竞赛三等奖

8、2017年东南大学青年教师微课竞赛提名奖

9、2018年江苏省教育教学与研究成果奖（研究类）二等奖 （3/6）

10、2021年东南大学教学成果奖二等奖 （3/5)

11、2019年国家级SRTP项目指导教师

12、2017-2018年校级SRTP项目（重大优秀奖）指导教师

主持科研项目：

1、国家自然科学基金面上项目 (No.82173852)；名称：基于TDO-Kyn-AhR和跨损伤DNA合成的新型四价铂配合物对人口腔鳞癌的抗肿瘤耐药作用及机制研究；研究起止年月：2022.01-2025.12；在研，项目负责人；

2、国家自然科学基金青年科学基金项目 (No.81503099)；名称：基于CK2和DNA损伤修复的新型四价铂复合物的抗肿瘤机制的研究；研究起止年月：2016.01-2018.12；已结题，项目负责人；

3、江苏省自然科学基金青年科学基金项目 (BK20150643)；名称：基于CK2介导DNA损伤修复的新型四价铂复合物Cx-platin抗肿瘤机制研究；研究起止年月：2015.07-2018.06；已结题（优秀），项目负责人；

4、东南大学高水平论文项目 (No.2242017K41024)；名称：基于多靶点耐药的新型四价铂复合物的抗肿瘤作用及机制研究；研究起止年月：2017.03-2019.12；已结题，项目负责人；

5、东南大学优秀青年教师科学研究项目(No.2242019R40045); 名称：基于免疫耐受蛋白TDO新型四价铂复合物及靶向纳米材料抗肿瘤耐药作用及机制研究；研究起止年月：2019.01-2021.12；已结题，项目负责人；

教学项目：

1、2021年江苏省高等教育学会评估委员会课题

2、2022年校级研究生课程思政教育教学改革与研究实践项目

3、2020年校级本科生课程思政教育教学改革与研究实践项目

4、2020年校级在线开放课程建设项目

5、2019年校级首届全英文精品课程建设项目

6、2019年校级教学改革研究项目 （结题优秀，15项/163项）

7、2018-2019年校级通选课程建设项目

学术组织：

   中国药理学会-化疗药理专委会青年委员（2021）

研究方向：

主要从事金属类化疗药物的肿瘤药理学和毒理学研究，主要研究方向：基于肿瘤耐药机制的新型四价铂前药的抗肿瘤耐药作用和机制研究。近五年来在Cancer Letters, Food and Chemical Toxicology, Biochemical Pharmacology, The Journal of Pharmacology and Experimental Therapeutics, Bioorganic Chemistry, European Journal of Medicinal Chemistry, 药学学报等本专业领域国际著名刊物上发表第一或通讯作者SCI论文26篇，CSCD3篇，累积影响因子100。担任了Cancer Letters, Molecular Pharmacology, European Journal of Medicinal Chemistry, Journal of Inorganic Biochemistry 等国际期刊的学术审稿人。在基于DNA损伤和修复领域的新型四价/二价铂复合物的抗肿瘤耐药作用和机制研究中取得了一定成果，获得了2018年江苏省教育教学与研究成果奖（研究类）二等奖（排第三）。

发表论文：

第一&通讯作者论文（时间倒序）：

17.  陈飞虹，赵德明，苟少华*. 具有抗肿瘤免疫治疗作用的铂类药物研究，中国药科大学学报

16. Xiaofeng Zou, Deming Zhao, Xin Wen, Feihong Chen*. NLG-919 combined with cisplatin to enhance inhibitory effect on cell migration and invasion via IDO1–Kyn–AhR pathway in human nasopharyngeal carcinoma cell. Canadian Journal of Physiology and Pharmacology, 2023, 101, 599-609.

15. Feihong Chen, Zhiwei Wang, Yuanjiang Wang, Shaohua Gou*. Circumventing drug resistance through a CK2-targeted combination via attenuating endogenous AhR-TLS-promoted genomic instability in human colorectal cancer cells. Food and chemical Toxicology, 2023, 176, 113774.

14.  田文源，陈飞虹*. IDO1 抑制剂联合替莫唑胺对人脑胶质瘤的协同抗肿瘤作用研究, 药学学报[J], 2022, 057(003), 707-715.

13. Feihong Chen, Gang Xu, Wenyuan Tian, Shaohua Gou*. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability. Biochemical Pharmacology, 2021, 193, 114785.

12. Xing Wang, Yuanjiang Wang, Shaohua Gou, Feihong Chen*. A trifunctional Pt(II) complex alleviates the NHEJ/HR-related DSBs repairs to evade cisplatin-resistance in NSCLC. Bioorganic Chemistry, 2020, 104, 104210.

11. Qinqin Liu, Shixian Hua, Xingyi Wang, Feihong Chen*, Shaohua Gou*. The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma. Cancer Immunology Immunotheraphy. 2020, 70，497-508.

10. Xinyi Wang, Feihong Chen*, Shaohua Gou*. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC. Bioorganic Chemistry, 2020, 104, 104234.

9. Feihong Chen, Sinan Pei, Xing Wang, Qian Zhu Shaohua Gou*. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immuneresistance. Biochemical and Biophysical Research Communications, 2020, 521, 753-761.

8. Shixian Hua, Xinyi Wang, Feihong Chen*, Shaohua Gou*. Novel conjugates with dual suppression of glutathione  S- transferases andtryptophan-2,3-dioxygenase activities for improving hepatocellular carcinomatherapy. Bioorganic Chemistry, 2019, 92, 103191.

7. Feihong Chen, Shuchen Sun, Nannan Liu, Sinan Pei, Qian Zhu, Xinyi Wang and Shaohua Gou*. Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair. Anti-cancer Drugs, 2019, 30，774-783.

6. Feihong Chen, Xiufeng Jin, Jian Zhao, Shaohua Gou*. DN604: A platinum(II) drugcandidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells. Experimental Cell Research, 2018, 364, 68-83.

5. Feihong Chen, Xiaochao Huang, Mian Wu, Shaohua Gou*, Weiwei Hu. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response. Cancer Letters, 2017, 385, 168-178.

4. Feihong Chen, Xiaodong Qin, Gang Xu, Shaohua Gou*, Xiufeng Jin. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-kappa B pathways. Biochemical Pharmacology, 2017, 135, 50-68.

3. Feihong Chen, Gang Xu, Xiaodong Qin, Xiufeng Jin and Shaohua Gou*. Hybrid of DNA-targeting chlorambucil with Pt(IV) species to reverse drug resistance. The Journal of Pharmacology and Experimental Therapeutics, 2017, 363(2), 221-239.

2. Feihong Chen, Xinyi Wang, Xiufeng Jin, Jian Zhao, Shaohua Gou*. Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs. Oncotarget, 2017, 8(19), 30933-30955.

1. Feihong Chen*, Dan Wang. Inhibition of glioblastoma growth and invasion by 125I brachytherapy in rat glioma model. American Journal of Translational Research, 2017, 9(5), 2243-2254.

共同第一作者论文：

8. Zhiwei Wang#, Feihong Chen#, Yuanjiang Wang, Shaohua Gou*. Blockade of chemo-resistance to 5-FU by a CK2-targeted combination via attenuating AhR-TLS-promoted genomic instability in human colon cancer cells. Toxicology and Applied Pharmacology, 2023, 475, 116647.

7. Hong Chen#, Feihong Chen#, Sinan Pei, Shaohua Gou*. Pomalidomidehybrids act as proteolysis targeting chimeras: Synthesis, anticancer activityand B-Raf degradation. Bioorganic Chemistry, 2019, 87, 191-199.

6. Shixian Hua#, Feihong Chen#, Gang Xu, Shaohua Gou*. Multifunctional platinum(IV) complexes as immune-stimulatory agents to promote cancer immune-chemotherapy by inhibiting tryptophan-2,3 dioxygenase. European Journal of Medicinal Chemistry, 2019, 169, 29-41.

5. Shixian Hua#, Feihong Chen#, Xinyi Wang, Yuanjiang Wang, Shaohua Gou*. Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immune-modulators. Journal of Inorganic Biochemistry, 2019, 195, 130-140.

4. Hong Chen#, Feihong Chen#, Xinyi Wang, Shaohua Gou*. Multifunctional Pt(IV) complexes containing a glutathione S-transferase inhibitor lead to enhancing anticancer activity and preventing metastasis of osteosarcoma cells. Metallomics, 2019, 11(2), 317-326.

3. Hong Chen#, Feihong Chen#, Weiwei Hu, Shaohua Gou*. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria. Journal of Inorganic Biochemistry, 2018, 180, 119-128.

2. Hong Chen#, Feihong Chen#, Nannan Liu, Xinyi Wang, Shaohua Gou*. Chemically induced degradation of CK2 by proteolysis targeting chimer as T based on aubiquitin–proteasome pathway. Bioorganic Chemistry, 2018, 81, 536- 544.

1. Zhiping Zhou#, Feihong Chen#, Gang Xu, Shaohua Gou*, Study on thecytotoxic activity of platinum(II) complexes of(1R,2R)-N-1-cyclopentyl-1,2-cyclohexanediamine with substituted malonate derivatives. Bioorganic Medicinal Chemistry Letters, 2016, 26(2), 322-327.